Clinical assessment of carotid atherosclerosis inflammation by positron emission tomography

Current Molecular Medicine

Volumn 13, Issue 10, 2013, Pages 1646-1652

  Shalhoub, J ^a   Oskrochi, Y ^a   Davies, A H ^a   Owen, D R J ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Atherosclerosis; Carotid; Imaging; Inflammation; Plaque; Positron emission tomography

Indexed keywords

ATORVASTATIN; CHOLINE; DALCETRAPIB; FLUORODEOXYGLUCOSE F 18; N SEC BUTYL 1 (2 CHLOROPHENYL) N METHYL 3 ISOQUINOLINECARBOXAMIDE C 11; PLACEBO; PROTEIN; SIMVASTATIN; TRANSLOCATOR PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CARDIOVASCULAR RISK; CAROTID ATHEROSCLEROSIS; CAROTID ENDARTERECTOMY; COMPUTER ASSISTED TOMOGRAPHY; CORONARY ARTERY DISEASE; FEMORAL ARTERY; HUMAN; INFLAMMATION; MACROPHAGE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC);

CAROTID ARTERY DISEASES; HUMANS; INFLAMMATION; POSITRON-EMISSION TOMOGRAPHY;

EID: 84889075954     PISSN: 15665240     EISSN: 18755666     Source Type: Journal    
DOI: 10.2174/1566524013666131111130334     Document Type: Article

References (50)

1. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 1999; 340: 115-26.
2. Mosser DM, Edwards JP. Exploring the full spectrum of macrophage activation. Nat Rev Immunol 2008; 8: 958-69.
3. Shalhoub J, Falck-Hansen MA, Davies AH, Monaco C. Innate immunity and monocyte-macrophage activation in atherosclerosis. J Inflamm (Lond) 2011; 8: 9.
4. Roger VL, Go AS, Lloyd-Jones DM, et al. Heart Disease and Stroke Statistics-2012 Update. Circulation 2012; 125: e2-e220.
5. Rudd JH, Warburton EA, Fryer TD, et al. Imaging atherosclerotic plaque inflammation with [18F]-fluorodeoxyglucose positron emission tomography. Circulation 2002; 105: 2708-11.
6. Tawakol A, Migrino RQ, Bashian GG, et al. In vivo 18F-fluorodeoxyglucose positron emission tomography imaging provides a noninvasive measure of carotid plaque inflammation in patients. J Am Coll Cardiol 2006; 48: 1818-24.
7. Rudd JH, Myers KS, Bansilal S, et al. Atherosclerosis inflammation imaging with 18F-FDG PET: carotid, iliac, and femoral uptake reproducibility, quantification methods, and recommendations. J Nucl Med 2008; 49: 871-8.
8. Davies JR, Rudd JH, Fryer TD, et al. Identification of culprit lesions after transient ischemic attack by combined 18F fluorodeoxyglucose positron-emission tomography and high-resolution magnetic resonance imaging. Stroke 2005; 36: 2642-7.
9. Graebe M, Pedersen SF, Borgwardt L, et al. Molecular pathology in vulnerable carotid plaques: correlation with [18]-fluorodeoxyglucose positron emission tomography (FDG-PET). Eur J Vasc Endovasc Surg 2009; 37: 714-21.
10. Pedersen S, Graebe M, Fisker H, et al. Gene expression and 18FDG uptake in atherosclerotic carotid plaques. Nucl Med Commun 2010; 31: 423-9.
11. Pedersen S, Graebe M, Hag AMF, et al. Microvessel Density But Not Neoangiogenesis Is Associated with 18F-FDG Uptake in Human Atherosclerotic Carotid Plaques. Mol Imaging Biol 2012; 14: 384-92.
12. Kwee RM, Truijman MTB, Mess WH, et al. Potential of Integrated [18F] Fluorodeoxyglucose Positron-Emission Tomography/CT in Identifying Vulnerable Carotid Plaques. AJNR Am J Neuroradiol 2011; 32: 950-4.
13. Tahara N, Kai H, Ishibashi M, et al. Simvastatin Attenuates Plaque Inflammation: Evaluation by Fluorodeoxyglucose Positron Emission Tomography. J Am Coll Cardiol 2006; 48: 1825-31.
14. Lee SJ, On YK, Lee EJ, et al. Reversal of vascular 18F-FDG uptake with plasma high-density lipoprotein elevation by atherogenic risk reduction. J Nucl Med 2008; 49: 1277-82.
15. Fayad ZA, Mani V, Woodward M, et al. Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial. Lancet 2011; 378: 1547-59.
16. Bural GG, Torigian DA, Chamroonrat W, et al. FDG-PET is an effective imaging modality to detect and quantify age-related atherosclerosis in large arteries. Eur J Nucl Med Mol Imaging 2008; 35: 562-9.
17. Yun M, Jang S, Cucchiara A, Newberg AB, Alavi A. 18F FDG uptake in the large arteries: a correlation study with the atherogenic risk factors. Semin Nucl Med 2002; 32: 70-6.
18. Wykrzykowska J, Lehman S, Williams G, et al. Imaging of inflamed and vulnerable plaque in coronary arteries with 18F-FDG PET/CT in patients with suppression of myocardial uptake using a low-carbohydrate, high-fat preparation. J Nucl Med 2009; 50(4): 563-8.
19. Alexanderson E, Slomka P, Cheng V, et al. Fusion of positron emission tomography and coronary computed tomographic angiography identifies fluorine 18 fluorodeoxyglucose uptake in the left main coronary artery soft plaque. J Nucl Cardiol 2008; 15: 841-3.
20. Rominger A, Saam T, Wolpers S, et al. 18F-FDG PET/CT identifies patients at risk for future vascular events in an otherwise asymptomatic cohort with neoplastic disease. J Nucl Med 2009; 50: 1611-20.
21. Marnane M, Merwick A, Sheehan OC, et al. Carotid plaque inflammation on 18F-fluorodeoxyglucose positron emission tomography predicts early stroke recurrence. Ann Neurol 2012; 71: 709-18.
22. Moustafa RR, Izquierdo-Garcia D, Fryer TD, et al. Carotid plaque inflammation is associated with cerebral microembolism in patients with recent transient ischemic attack or stroke: a pilot study. Circ Cardiovasc Imaging 2010; 3: 536-41.
23. Muntendam P, McCall C, Sanz J, Falk E, Fuster V. The BioImage Study: novel approaches to risk assessment in the primary prevention of atherosclerotic cardiovascular disease-study design and objectives. Am Heart J 2010; 160: 49-57+e1.
24. Papadopoulos V, Baraldi M, Guilarte TR, et al. Translocator protein (18kDa): new nomenclature for the peripheral-type benzodiazepine receptor based on its structure and molecular function. Trends Pharmacol Sci 2006; 27: 402-9.
25. Banati RB, Newcombe J, Gunn RN, et al. The peripheral benzodiazepine binding site in the brain in multiple sclerosis: quantitative in vivo imaging of microglia as a measure of disease activity. Brain 2000; 123: 2321-37.
26. Cagnin A, Myers R, Gunn RN, et al. In vivo visualization of activated glia by[11C] (R)-PK11195-PET following herpes encephalitis reveals projected neuronal damage beyond the primary focal lesion. Brain 2001; 124: 2014-27.
27. Edison P, Archer HA, Gerhard A, et al. Microglia, amyloid, and cognition in Alzheimer's disease: An [11C](R)PK11195-PET and [11C]PIB-PET study. Neurobiol Dis 2008; 32: 412-9.
28. Ramsay SC, Weiller C, Myers R, et al. Monitoring by PET of macrophage accumulation in brain after ischaemic stroke. Lancet 1992; 339: 1054-5.
29. Bird JL, Izquierdo-Garcia D, Davies JR, et al. Evaluation of translocator protein quantification as a tool for characterising macrophage burden in human carotid atherosclerosis. Atherosclerosis 2010; 210: 388-91.
30. Lamare F, Hinz R, Gaemperli O, et al. Detection and quantification of large-vessel inflammation with 11C-(R)-PK11195 PET/CT. J Nucl Med 2011; 52: 33-9.
31. Pugliese F, Gaemperli O, Kinderlerer AR, et al. Imaging of vascular inflammation with [11C]-PK11195 and positron emission tomography/computed tomography angiography. J Am Coll Cardiol 2010; 56: 653-61.
32. Gaemperli O, Shalhoub J, Owen DRJ, et al. Imaging intraplaque inflammation in carotid atherosclerosis with 11C-PK11195 positron emission tomography/computed tomography. Eur Heart J 2012; 33: 1902-10.
33. Rusjan PM, Wilson AA, Bloomfield PM, et al. Quantitation of translocator protein binding in human brain with the novel radioligand [18F]-FEPPA and positron emission tomography. J Cereb Blood Flow Metab 2011; 31: 1807-16.
34. Takano A, Arakawa R, Ito H, et al. Peripheral benzodiazepine receptors in patients with chronic schizophrenia: a PET study with [11C]DAA1106. Int J Neuropsychopharmacol 2010; 13: 943-50.
35. Endres CJ, Pomper MG, James M, et al. Initial Evaluation of 11C-DPA-713, a Novel TSPO PET Ligand, in Humans. J Nucl Med 2009; 50: 1276-82.
36. Van Camp N, Boisgard R, Kuhnast B, et al. In vivo imaging of neuroinflammation: a comparative study between [18F]PBR111, [11C]CLINME and [11C]PK11195 in an acute rodent model. Eur J Nucl Med Mol Imaging 2010; 37: 962-72.
37. Oh U, Fujita M, Ikonomidou V, et al. Translocator Protein PET Imaging for Glial Activation in Multiple Sclerosis. J Neuroimmune Pharmacol 2011; 6: 354-61.
38. Fujita M, Imaizumi M, Zoghbi SS, et al. Kinetic analysis in healthy humans of a novel positron emission tomography radioligand to image the peripheral benzodiazepine receptor, a potential biomarker for inflammation. Neuroimage 2008; 40: 43-52.
39. Owen DR, Howell OW, Tang S-P, et al. Two binding sites for [lsqb]3H[rsqb]PBR28 in human brain: implications for TSPO PET imaging of neuroinflammation. J Cereb Blood Flow Metab 2010; 30: 1608-18.
40. Owen DRJ, Gunn RN, Rabiner EA, et al. Mixed-Affinity Binding in Humans with 18-kDa Translocator Protein Ligands. J Nucl Med 2011; 52: 24-32.
41. Owen DR, Yeo AJ, Gunn RN, et al. An 18-kDa translocator protein (TSPO) polymorphism explains differences in binding affinity of the PET radioligand PBR28. J Cereb Blood Flow Metab 2012; 32: 1-5.
42. Boggs KP, Rock CO, Jackowski S. Lysophosphatidylcholine and 1-O-octadecyl-2-O-methyl-rac-glycero-3-phosphocholine inhibit the CDP-choline pathway of phosphatidylcholine synthesis at the CTP:phosphocholine cytidylyltransferase step. J Biol Chem 1995; 270: 7757-64.
43. Kato K, Schober O, Ikeda M, et al. Evaluation and comparison of 11C-choline uptake and calcification in aortic and common carotid arterial walls with combined PET/CT. Eur J Nucl Med Mol Imaging 2009; 36: 1622-8.
44. Bucerius J, Schmaljohann J, Bohm I, et al. Feasibility of 18F-fluoromethylcholine PET/CT for imaging of vessel wall alterations in humans-first results. Eur J Nucl Med Mol Imaging 2008; 35: 815-20.
45. Ben-Haim S, Kupzov E, Tamir A, Israel O. Evaluation of 18F-FDG uptake and arterial wall calcifications using 18F-FDG PET/CT. J Nucl Med 2004; 45: 1816-21.
46. Beer AJ, Haubner R, Sarbia M, et al. Positron emission tomography using [18F]Galacto-RGD identifies the level of integrin alpha(v)beta3 expression in man. Clin Cancer Res 2006; 12: 3942-9.
47. Beer AJ, Haubner R, Wolf I, et al. PET-based human dosimetry of 18F-galacto-RGD, a new radiotracer for imaging alpha v beta3 expression. J Nucl Med 2006; 47: 763-9.
48. Yao Y, Jiang Y, Sheng Z, et al. Analysis of in situ and ex vivo alphaVbeta3 integrin expression during experimental carotid atherogenesis. Int J Nanomedicine 2012; 7: 641-9.
49. Burtea C, Laurent S, Murariu O, et al. Molecular imaging of alpha v beta3 integrin expression in atherosclerotic plaques with a mimetic of RGD peptide grafted to Gd-DTPA. Cardiovasc Res 2008; 78: 148-57.
50. Tahara N, Kai H, Nakaura H, et al. The prevalence of inflammation in carotid atherosclerosis: analysis with fluorodeoxyglucose-positron emission tomography. Eur Heart J 2007; 28: 2243-8.